Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic
| Errataetall: |
ErratumIn: JAMA Ophthalmol. 2021 Feb 1;139(2):256. - PMID 33595604 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:139 |
|---|---|
| Enthalten in: |
JAMA ophthalmology - 139(2021), 2 vom: 01. Feb., Seite 240-242 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Billioti de Gage, Sophie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.02.2021 Date Revised 16.04.2021 published: Print ErratumIn: JAMA Ophthalmol. 2021 Feb 1;139(2):256. - PMID 33595604 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamaophthalmol.2020.5594 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318969203 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318969203 | ||
| 003 | DE-627 | ||
| 005 | 20231225170453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamaophthalmol.2020.5594 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM318969203 | ||
| 035 | |a (NLM)33331873 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Billioti de Gage, Sophie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2021 | ||
| 500 | |a Date Revised 16.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: JAMA Ophthalmol. 2021 Feb 1;139(2):256. - PMID 33595604 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a VEGFA protein, human |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a aflibercept |2 NLM | |
| 650 | 7 | |a 15C2VL427D |2 NLM | |
| 650 | 7 | |a Receptors, Vascular Endothelial Growth Factor |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Ranibizumab |2 NLM | |
| 650 | 7 | |a ZL1R02VT79 |2 NLM | |
| 700 | 1 | |a Drouin, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Desplas, David |e verfasserin |4 aut | |
| 700 | 1 | |a Cuenot, François |e verfasserin |4 aut | |
| 700 | 1 | |a Dray-Spira, Rosemary |e verfasserin |4 aut | |
| 700 | 1 | |a Weill, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Zureik, Mahmoud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA ophthalmology |d 2013 |g 139(2021), 2 vom: 01. Feb., Seite 240-242 |w (DE-627)NLM220905169 |x 2168-6173 |7 nnns |
| 773 | 1 | 8 | |g volume:139 |g year:2021 |g number:2 |g day:01 |g month:02 |g pages:240-242 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamaophthalmol.2020.5594 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 139 |j 2021 |e 2 |b 01 |c 02 |h 240-242 | ||